The Cell Cycle and Its Phases

The cell cycle is the ordered series of events by which a eukaryotic cell duplicates its contents and divides into two genetically identical daughter cells. It is conventionally divided into two grand periods: interphase, during which the cell grows and replicates its DNA, and the M phase (mitotic phase), during which the replicated chromosomes are segregated and the cell physically divides. Interphase itself is subdivided into three phases: G1 (Gap 1), S (Synthesis), and G2 (Gap 2). The full sequence reads: G1 → S → G2 → M → (back to G1) Each phase has one non-negotiable job. In G1, the cell grows in size, synthesizes proteins and organelles, and monitors its environment (nutrient availability, growth factor signals, DNA integrity) to decide whether to commit to another round of division. In S phase, the entire genome is replicated — each chromosome, consisting of a single DNA double helix, becomes two identical sister chromatids joined at the centromere and held together by Cohesin complexes. In G2, the cell continues to grow, synthesizes the proteins needed for mitosis, and checks that replication was completed accurately before committing to division. In M phase, the duplicated chromosomes condense, align, and are pulled apart into two nuclei (mitosis), followed by cytokinesis, which physically cleaves the cell in two. A crucial terminological distinction: the "gap" in G1 and G2 does not mean idleness. These are misleadingly named historically — early cytologists, looking only at chromosome morphology under the microscope, saw no visible change during these intervals and assumed nothing was happening. We now know G1 and G2 are biochemically active decision windows, arguably more important to the fidelity of the cycle than the synthesis and division phases themselves, because this is where checkpoints operate — surveillance mechanisms that halt progression if conditions are not met. Cells that exit the cycle altogether (e.g., most neurons, differentiated muscle cells) enter a quiescent state called G0, a reversible or, in some cell types, essentially permanent withdrawal from the cycle.

Step 1 — G1: growth and commitment. A newborn daughter cell enters G1 roughly at half the volume of its mother. It synthesizes RNA and protein, rebuilds organelle number, and integrates external signals — mitogens, growth factor receptor signaling, nutrient status — to determine whether conditions favor another division. Late in G1 (in mammalian cells) or at a comparable point in yeast (called START in budding yeast), the cell passes the restriction point (R point), after which it is committed to complete the cycle even if growth factors are withdrawn. Before the restriction point, the decision is reversible; after it, the cycle proceeds autonomously. This commitment step foreshadows the molecular machinery — Cyclins and Cyclin-Dependent Kinases — that physically encodes the decision as a switch-like burst of kinase activity.

Step 2 — S phase: replicating the genome exactly once. At the G1/S transition, replication origins that were licensed during G1 (foreshadowing DNA Replication Licensing and Origin Firing) begin firing. DNA polymerases, helicases, and associated replisome proteins duplicate the genome, converting each unreplicated chromosome into a pair of sister chromatids. Newly synthesized DNA is immediately packaged with newly synthesized histones, and cohesin is loaded to hold the sister chromatids together until anaphase. In a typical human cell, S phase takes roughly 6–8 hours, during which about 6 billion base pairs (the diploid genome) are copied with extraordinary fidelity — the replication error rate is roughly 1 mistake per 10⁹–10¹⁰ base pairs, thanks to polymerase proofreading and mismatch repair.

Step 3 — G2: quality control and preparation for division. With replication complete, the cell enters G2, synthesizing tubulin and other proteins needed to build the mitotic spindle, and centrosomes (already duplicated during S phase) mature. The G2/M checkpoint surveys the genome for unreplicated or damaged DNA; unresolved damage halts entry into mitosis, giving repair machinery time to act. Only when the genome passes inspection does the cell activate the master mitotic kinase (Cdk1–cyclin B, again foreshadowing the cyclin/CDK article) and commit irreversibly to mitosis.

Step 4 — M phase: segregation and division. Mitosis itself unfolds through prophase, prometaphase, metaphase, anaphase, and telophase — condensing chromosomes, assembling a bipolar spindle, aligning chromosomes at the metaphase plate, severing cohesin to separate sister chromatids, and reforming two nuclei — a sequence developed fully in Overview of Mitosis and Its Stages. Cytokinesis then partitions the cytoplasm, typically overlapping with telophase, yielding two daughter cells each with a complete diploid genome and a restored G1 identity.

Timing in a typical proliferating human cell (roughly 24-hour cycle):

These numbers vary enormously by cell type — early frog and fly embryos compress the entire cycle to under 30 minutes by skipping G1 and G2 almost entirely, relying on stockpiled maternal proteins — but the qualitative point holds broadly: interphase dominates, and mitosis, though visually dramatic, is the shortest chapter.

Interphase organization. Within interphase, the nucleus is not a passive bag of DNA. Chromatin exists in two broad states — open, transcriptionally active euchromatin and condensed, largely silent heterochromatin — organized into distinct chromosome territories occupying non-random nuclear positions. Replication does not happen everywhere at once: origins fire in a defined temporal program, with gene-rich euchromatin typically replicating early in S phase and heterochromatin replicating late. This spatial and temporal organization is invisible under a simple light microscope (hence the historical "gap" misnomer) but is essential — errors in replication timing correlate with genomic instability. The nuclear envelope, nucleolus (site of ribosome biogenesis), and cytoskeletal architecture are all maintained through G1, S, and G2, then dismantled and rebuilt during mitosis.

Mapping the phases with radioactive thymidine (Howard & Pelc, 1953). Before biochemistry, cell cycle phases were purely descriptive stages seen under the microscope. Alma Howard and Stephen Pelc, working with broad bean (Vicia faba) root tip cells, applied radioactive phosphate (³²P) and, crucially, used autoradiography to track when DNA synthesis occurred relative to visible mitosis. They discovered something unexpected: DNA synthesis was not continuous through interphase, nor did it occur during mitosis. Instead, it was confined to a discrete window separated from mitosis by measurable gaps. This directly established the G1–S–G2–M framework and gave the phases their names — Howard and Pelc explicitly coined "G1" and "G2" for the gaps flanking the synthesis (S) period, precisely because no DNA synthesis, and to their microscopes no other obvious change, was detectable there.

Refining phase durations with tritiated thymidine pulse-labeling. The technique was sharpened using ³H-thymidine, a radioactive nucleotide precursor that incorporates specifically into newly synthesized DNA. Researchers pulse-labeled a population of dividing cells for a brief interval, then chased (washed out the label) and examined cells at successive time points by autoradiography, watching the labeled cohort of cells move through S, G2, mitosis, and back into G1. By measuring the time from labeling to the appearance of labeled mitotic figures, and the time for labeled mitoses to disappear, investigators could calculate the duration of S, G2, M, and (by subtraction from total cycle time) G1 in a given cell population — the very numbers summarized in the mechanism table above. This "percent labeled mitoses" (PLM) method remains a classic quantitative tool in cell cycle kinetics.

Bromodeoxyuridine (BrdU) labeling. A non-radioactive descendant of the same logic: BrdU, a thymidine analog, is incorporated into DNA only during S phase and later detected with a specific antibody. Because it avoids radioactivity, BrdU labeling (and later, similar analogs like EdU) became the standard modern tool for identifying which cells in a tissue are actively synthesizing DNA — used extensively in developmental biology, cancer diagnostics, and neurogenesis research to find dividing cells in situ.

Cell-fusion experiments proving the cycle is driven by diffusible cytoplasmic factors (Rao & Johnson, 1970s). Perhaps the most conceptually decisive experiment came from Potu Rao and Robert Johnson, who used Sendai virus to fuse mammalian cells arrested at different cell cycle stages and asked what happened to each nucleus. Three results were pivotal:

• Fusing an S-phase cell with a G1-phase cell caused the G1 nucleus to begin DNA synthesis prematurely — it was induced into S phase ahead of schedule.
• Fusing an S-phase cell with a G2-phase cell did not induce the G2 nucleus to re-replicate; it stayed in G2 until the cycle proceeded normally, demonstrating that a cell that has already completed replication is somehow protected from re-replicating in the same cycle.
• Fusing a mitotic cell with a cell in any interphase stage caused premature chromosome condensation (PCC) of the interphase chromatin — G1 chromatin condensed into single-chromatid rods, S-phase chromatin condensed into a fragmented "pulverized" pattern reflecting incomplete replication, and G2 chromatin condensed into normal-looking double-chromatid structures.

The interpretation was transformative: cell cycle transitions are driven by diffusible cytoplasmic activities that can act in trans across a shared cytoplasm, not by an intrinsic, nucleus-autonomous clock. An S-phase cytoplasm contains an activity ("S-phase promoting factor") sufficient to trigger DNA synthesis in a naïve G1 nucleus; a mitotic cytoplasm contains an activity ("mitosis-promoting factor," MPF) sufficient to force chromosome condensation in any interphase nucleus regardless of its own state of readiness. This result — years before any cyclin or CDK was cloned — is the direct experimental ancestor of the discovery of MPF (Masui and Markert, in frog oocytes) and ultimately of cyclins and cyclin-dependent kinases, establishing that the cell cycle is governed by regulatory proteins whose activity rises and falls, rather than by chromosome structure alone dictating its own fate.

Yeast genetics (Hartwell, Nurse — foreshadowed here, developed fully elsewhere). Complementary genetic evidence came from screens for temperature-sensitive cell-division-cycle (cdc) mutants in budding and fission yeast (Leland Hartwell and Paul Nurse, respectively), which identified genes required for passage through specific cell cycle transitions — work that, together with the Rao-Johnson cytoplasmic-factor experiments, converged on the discovery of cyclin-dependent kinases and earned the 2001 Nobel Prize in Physiology or Medicine (shared with Tim Hunt, who discovered cyclins). That molecular story belongs properly to Cyclins and Cyclin-Dependent Kinases, but its evidentiary roots lie squarely in the phase-mapping and fusion experiments described here.

Example 1 — Calculating phase durations from a labeling experiment. A researcher pulse-labels a growing culture of cultured human fibroblasts with ³H-thymidine for a short interval, then fixes samples at successive times and scores the fraction of mitotic cells that are labeled (percent labeled mitoses, PLM). The data show:

• Labeled mitotic figures first appear 3 hours after the pulse.
• The PLM curve rises, peaks near 100%, then falls; the second rise (a new wave of labeled mitoses, from cells that were in S phase during the pulse, replicated, and returned via a second cycle) occurs 24 hours after the first peak.
• Labeled mitoses are absent by 11 hours (all initially labeled S-phase cells have divided) and reappear at hour 24.

Interpretation:

• The gap between pulse and first labeled mitosis (3 hours) is the average G2 duration — the time it takes cells that were finishing S phase at pulse time to reach mitosis.
• The interval during which labeled mitoses persist (from hour 3 to hour 11, i.e., 8 hours) approximates the duration of S phase — the spread reflects cells that were at different points within S at the moment of the pulse.
• The interval between successive waves of labeled mitoses (24 hours) is the total cell cycle length.
• G1 duration is then obtained by subtraction: total cycle − (S + G2 + M). If M is measured independently (e.g., by mitotic index, roughly 1 hour), then G1 ≈ 24 − 8 − 3 − 1 = 12 hours.

This is exactly the logic — and roughly the numbers — that established the durations in the phase table above, using nothing more exotic than a radioactive nucleotide and a stopwatch.

Example 2 — Reasoning about a clinical/pharmacological scenario. A drug (a hypothetical DNA-damaging chemotherapeutic) is applied to a population of rapidly dividing tumor cells. Flow cytometry, which measures DNA content per cell (using a DNA-binding fluorescent dye), is used to determine the distribution of cells across the cycle before and after treatment. DNA content is:

• 2C in G1 (one copy of the diploid genome, unreplicated)
• between 2C and 4C during S phase (partially replicated)
• 4C in G2 and M (fully replicated, not yet divided)

Before treatment, the histogram shows: 50% of cells at 2C (G1), 35% between 2C and 4C (S), 15% at 4C (G2/M) — a typical actively cycling population. After 24 hours of drug exposure, the histogram shifts: the 4C peak balloons to 70% of cells, the 2C peak shrinks to 20%, and the S-phase fraction drops to 10%. Reasoning: the drug has caused G2/M arrest — cells have completed S phase (reaching 4C DNA content) but are failing to proceed into and through mitosis, most likely because DNA damage has activated the G2/M checkpoint, halting Cdk1–cyclin B activation until repair is attempted. This is precisely the rationale behind many genotoxic chemotherapies: by damaging DNA and triggering checkpoint arrest (and, if damage is irreparable, apoptosis), they preferentially kill rapidly cycling tumor cells whose checkpoints are engaged, while relying on the fact that many cancer cells have partially compromised checkpoint machinery (e.g., mutant p53) that makes this arrest leaky and death more likely than in normal tissue — though this same checkpoint leakiness is also why chemotherapy resistance can evolve.

Leland Hartwell built the genetic case for the cell cycle as a series of discrete, gene-controlled, ordered steps rather than a black-box clock. Working with budding yeast (Saccharomyces cerevisiae) in the late 1960s and 1970s, Hartwell isolated temperature-sensitive mutants that arrested at specific, reproducible points in the cycle when shifted to restrictive temperature — he called these cdc (cell-division-cycle) genes. Crucially, he identified CDC28 as controlling passage through START, the yeast equivalent of the restriction point, showing genetically that commitment to a new cycle is a discrete, controllable event rather than an inevitable drift. He also formalized the concept of the checkpoint — a surveillance mechanism, exemplified by the observation that DNA damage blocks cell cycle progression until repair occurs, ensuring order is enforced even when the underlying process (replication, repair) runs at variable, unpredictable speed.

Cancer diagnosis and therapy. Flow cytometric measurement of DNA content (the 2C/S/4C distribution described above) is a routine tool for assessing tumor proliferation rates and for monitoring how chemotherapies perturb cycle progression. Many chemotherapeutic agents are explicitly designed around cell cycle phase specificity: S-phase-specific drugs (e.g., cytarabine, methotrexate) exploit active DNA synthesis; M-phase-specific drugs (e.g., vincristine, paclitaxel) disrupt spindle function; and understanding checkpoint biology explains why combining a DNA-damaging agent with a checkpoint inhibitor can selectively sensitize checkpoint-deficient tumor cells to death.

Regenerative medicine and tissue engineering. Knowing which cell populations remain in G0 (quiescent stem cells, terminally differentiated neurons and cardiomyocytes) versus actively cycling (skin basal layer, gut epithelium, hematopoietic progenitors) shapes strategies for tissue repair, from bone marrow transplantation to attempts at inducing cardiomyocyte proliferation after myocardial infarction.

Agricultural biotechnology. Controlling the cell cycle in plant meristems (root and shoot tips, where Howard and Pelc did their founding experiment) underlies techniques for inducing polyploidy, synchronizing cell division for tissue culture and micropropagation, and understanding stress-induced cell cycle arrest in crops.

Developmental biology. Early embryonic cleavage divisions (e.g., in Xenopus and Drosophila) that skip G1 and G2 entirely illustrate how the core machinery can be radically rewired, informing our understanding of how gap phases were layered onto an ancestral, faster oscillator during evolution of multicellular developmental control.

Diagnostics using BrdU/EdU labeling. Modern pulse-labeling with EdU (a click-chemistry-compatible thymidine analog) is standard in research on tissue regeneration, neurogenesis (identifying newborn neurons in the adult brain), and cancer pathology (assessing proliferative index in biopsy samples), directly descended from the Howard–Pelc and tritiated-thymidine methodology.

Ask the tutor: How do cyclins and CDKs physically translate "pass the checkpoint" into "start the next phase"?